Drug Information

Drug General Information
Drug ID
D03FIA
Former ID
DCL000628
Drug Name
Rituxan Immunology
Drug Type
Antibody
Indication Pemphigus disease [ICD9: 694.4; ICD10:L10] Phase 3 [525110]
Company
Genentech
Structure
Download
2D MOL

3D MOL
Formula
C28H34N4O3
Canonical SMILES
CC12C(C(CC(O1)N3C4=C(CCCC4)C5=C6C(=C7C8=C(N2C7=C53)CCCC<br />8)CNC6=O)NC)OC
InChI
1S/C28H34N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h17,20,26,29H,4-13H2,1-3H3,(H,30,33)
InChIKey
VJTABXDSZIOUGU-UHFFFAOYSA-N
PubChem Compound ID
23644059
PubChem Substance ID
134339164, 134340570
Target and Pathway
Target(s) B-lymphocyte antigen CD20 Target Info [550797]
KEGG Pathway Hematopoietic cell lineage
References
Ref 525110ClinicalTrials.gov (NCT02383589) A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus Vulgaris. U.S. National Institutes of Health.
Ref 550797Clinical pipeline report, company report or official report of Genentech (2009).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.